AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01091493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg administered once a day for 5 days
Study NCT03578991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart pillbox
Description: The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
Study NCT03578991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive digital platform
Description: The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
Study NCT02533830 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sugarless gum
Description: One Stick of Sugarless Gum (Samara for food \& Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation
Study NCT02533830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional management
Description: Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
Study NCT02622516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group (IG)
Description: Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members.
Study NCT02622516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group (CG)
Description: The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members.
Study NCT03342690 — intervention group
Intervention type: DRUG
Intervention: Eplerenone
Description: In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions.
Study NCT02554812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody
Study NCT02573129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Meat Restricted
Description: restrict intake of red meat while a Mediterranean diet
Study NCT02554812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Anti-4-1BB antibody
Study NCT02554812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600
Description: OX40 Agonist
Study NCT03087071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT03087071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT03193086 — intervention group
Intervention type: DRUG
Intervention: Alemtuzumab
Description: Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
Study NCT03317626 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cold Stimulus (ice) Test
Description: Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
Study NCT03757650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Subsalicylate
Description: omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
Study NCT04315688 — intervention group
Intervention type: DRUG
Intervention: insulin degludec
Description: Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
Study NCT04022785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT04022785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRD4 Inhibitor PLX51107
Description: Given PO
Study NCT00756184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TDA adherence monitor for travoprost therapy
Description: monitoring adherence to travoprost therapy
Study NCT00756184 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TDA and travoprost monotherapy
Description: Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
Study NCT04395638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3200IU Vitamin D3 per day for 8 weeks
Description: 3200IU Vitamin D3 per day for 8 weeks
Study NCT04395638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20,000IU Vitamin D3 per week for 8 weeks
Description: 20,000IU Vitamin D3 per week for 8 weeks
Study NCT02516293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, nutritional and pharmaceutical counseling
Description: Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
Study NCT03088748 — intervention group
Intervention type: DEVICE
Intervention: Journey II posterior cruciate retaining total knee arthroplasty
Study NCT03088748 — intervention group
Intervention type: DEVICE
Intervention: Journey II posterior bi-cruciate retaining total knee arthroplasty
Study NCT00359944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-3933
Description: 5mg twice daily
Study NCT00359944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-3933
Description: AC-3933, 20 mg twice daily
Study NCT00359944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar Pill twice daily
Study NCT03326414 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Constant PEEP - low tidal volume
Description: The respirator is set according to study protocol
Study NCT03326414 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Constant PEEP - high tidal volume
Description: The respirator is set according to study protocol
Study NCT03326414 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: constant tidal volume - low PEEP
Description: The respirator is set according to study protocol
Study NCT03326414 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: constant tidal volume - high PEEP
Description: The respirator is set according to study protocol
Study NCT01968291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach-back
Description: Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
Study NCT01730833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Given IV
Study NCT01730833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT01730833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT01730833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT02295215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise Training for 4 months
Study NCT02593422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
Study NCT02593422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fact Writing (Control)
Description: Participants will be asked to write about the facts of their experience with ovarian cancer
Study NCT05385081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: genomic profiling
Description: next generation sequencing
Study NCT01921374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sleep parameters
Description: Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
Study NCT01921374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hormonal profile
Description: To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
Study NCT01921374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflammatory profile
Description: To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
Study NCT01921374 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cardiovascular profile
Description: To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
Study NCT01921374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Metabolic profile
Description: To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
Study NCT03134365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal
Description: Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
Study NCT03134365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined meal
Description: Combined meal.
Study NCT01323270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months.
Study NCT01323270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Repevax
Description: 0.5 mL dose, given at 0 months.
Study NCT01323270 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5 mL dose, given at 0, 2 and 6 months.
Study NCT01323270 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Repevax
Description: 0.5 mL dose, given at 0 months.
Study NCT01212211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: change in drug therapy
Description: Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
Study NCT04043754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery: Periodontal surgery with Membrane
Description: Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
Study NCT04043754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery with Platlet Rich fibrin
Description: Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
Study NCT03473106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet use
Description: Surgery requiring a pneumatic tourniquet on the thigh
Study NCT00165750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONEPEZIL HYDROCHLORIDE
Description: One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
Study NCT03496350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: Culturally adapted transdiagnostic internet-delivered CBT in Arabic
Study NCT03351816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation of atrial fibrillation
Description: Pulmonary vein isolation by radiofrequency or cryoablation.
Study NCT03351816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioversion
Description: External electric shock delivery under general anesthesia.
Study NCT02154620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar plate
Description: An anatomically countoured volar plate is implanted through a Henry's incision.
Study NCT02154620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthes TCP volar plate
Study NCT02810301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic ES1
Description: B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
Study NCT02810301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
Study NCT01904916 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Histological biopsy procedure
Study NCT02995083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
Description: Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
Study NCT02995083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 ml
Description: Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
Study NCT02995083 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Air 10 ml
Description: Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
Study NCT02974335 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews with Stakeholders
Description: The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
Study NCT01613989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic hip surgery, operated under manual control
Description: : Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
Study NCT01613989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic hip surgery operated under navigation based on EOS imaging
Description: The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
Study NCT04532593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous adipose stem cell injection
Description: Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
Study NCT04532593 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: saline will be injected underneath skin graft (0.05 ml/cm2).
Study NCT02109432 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Directed Pedal Desk
Description: participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
Study NCT02109432 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facilitated Pedal Desk
Description: participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
Study NCT02109432 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facilitated Pedal Desk with Pedometer
Description: participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
Study NCT02554812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: Anti-M-CSF
Study NCT02554812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: TLR9 agonist
Study NCT03793231 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: fungalAi platform technology
Description: Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
Study NCT03409406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Intervention
Description: This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
Study NCT02573129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Meat Rich
Description: Mediterranean diet rich in red meat
Study NCT01070693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open mesh inguinal hernia repair
Description: Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
Study NCT01070693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System
Description: Prolene Hernia System
Study NCT01070693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Description: Lichtenstein technique
Study NCT01949623 — intervention group
Intervention type: OTHER
Intervention: Anterior Chamber (AC) tap
Description: Aqueous Samples will be collected for measurement of biomarkers
Study NCT02152059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Description: BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
Study NCT00770042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)